| | Science | | | | | |
|----------|---|--|--|--|--|--|
| 1 | Science | | | | | |
| 2 | MAAAS | | | | | |
| 3 | | | | | | |
| 4 | Supplementary Materials for | | | | | |
| 5 | | | | | | |
| 6 | Structures of Respiratory Syncytial Virus G Antigen Bound to Broadly | | | | | |
| 7 | Neutralizing Antibodies | | | | | |
| 8 | | | | | | |
| 9 | Stanislav O. Fedechkin, Natasha L. George, Jacob T. Wolff, Lawrence M. Kauvan | | | | | |
| 10 | Rebecca M. DuBois* | | | | | |
| 11 | 1 1 1 1 0 1 | | | | | |
| 12 13 | *correspondence to: rmdubois@ucsc.edu | | | | | |
| 13 | | | | | | |
| 15 | This PDF file includes: | | | | | |
| 16 | This I DI The meduco. | | | | | |
| 17 | Fig. S1. Co-elution of RSV G-antibody complexes in solution. | | | | | |
| 18 | Fig. S2. Electron density maps and structural alignments of RSV G. | | | | | |
| 19 | Fig. S3. Schematic of RSV G interactions with anti-G antibodies. | | | | | |
| 20 | Fig. S4. Structural comparison of RSV G with CX3CL1 (fractalkine). | | | | | |
| 21 | Fig. S5. Isolated human anti-G mAbs and epitope characterization. | | | | | |
| 22 | Table S1. Crystallographic data collection and refinement statistics. | | | | | |
| 23 | | | | | | |
| | | | | | | |




Fig. S1. Co-elution of RSV G-antibody complexes in solution. (A, C, E) Superdex 200 size-exclusion chromatography purification traces of antibody-RSV G complexes. (B) Non-reducing SDS-PAGE of molecular weight markers in kD (MW), Fab 3D3 alone (lane 1), co-eluted Fab 3D3-RSV G¹⁶²⁻¹⁷² complex (lane 2), and RSV G¹⁶²⁻¹⁷² alone (lane 3). (D) Non-reducing SDS-PAGE of molecular weight markers in kD (MW) and co-eluted Fab 3D3-RSV G¹⁶¹⁻¹⁹⁷ complex (lanes 1 and 2). (F) Reducing SDS-PAGE of molecular weight markers in kD (MW), co-eluted scFv 2D10-RSV G¹⁶⁹⁻¹⁹⁸ complex (lane 1), and RSV G¹⁶⁹⁻¹⁹⁸ alone (lane 2).




Fig. S2. Electron density maps and structural alignments of RSV G. (A, D) Electron density maps around RSV G¹⁶²⁻¹⁷² (when bound to Fab 3D3), (B, E) Electron density maps around RSV G¹⁶¹⁻¹⁹⁷ (when bound to Fab 3D3). (C, F) Electron density maps around RSV G¹⁶⁹⁻¹⁹⁸ (when bound to scFv 2D10). The 2Fo-Fc electron density maps (in pink, panels A-C) and unbiased composite omit maps (in blue, panels D-F) are contoured at 1.0 σ. (G) Structural alignment of RSV G from all three structures. Note that in the Fab 3D3-RSV G¹⁶²⁻¹⁷² complex and Fab 3D3-RSV G¹⁶¹⁻¹⁹⁷ complex structures, there are two molecules of RSV G in the asymmetric unit. (H) Structural alignment of RSV G¹⁶¹⁻¹⁹⁷ with human RSV G cysteine noose structures determined previously by NMR (PDB entries 1kwd and 1kwe). The RMSD for the alignment of RSV G¹⁶¹⁻¹⁹⁷ with 1kwd is 1.0 Å and with 1kwe is 1.4 Å. (I) Structural alignment of RSV G¹⁶¹⁻¹⁹⁷ with bovine RSV G cysteine noose structure determined previously by NMR (PDB entries 1brv). The RMSD for the alignment of RSV G¹⁶¹⁻¹⁹⁷ with 1brv is 0.7 Å.




Fig. S3. Schematic of RSV G interactions with anti-G antibodies. (A) Model of membrane-bound G glycoprotein on the surface of the RSV virion or the surface of RSV-infected cells alone (left) or bound by bnmAbs 3D3 and 2D10 (right). **(B)** Model of soluble RSV G glycoprotein, which is secreted from RSV-infected cells and modulates CX3CR1⁺ immune cells, alone (left) or bound by bnmAbs 3D3 and 2D10 (right). **(C)** Zoom-in of RSV G CCD bound by bnmAbs 3D3 and 2D10. For clarity, only the variable regions of the bnmAbs are shown.




Fig. S4. Structural comparison of RSV G with CX3CL1 (fractalkine). (A) Structure of CX3CL1 (red) bound to the human cytomegalovirus G-protein coupled receptor US28 (grey) (PDB code 4XT1). US28 has 38% sequence identity with the human chemokine receptor CX3CR1. **(B)** Structure of CX3CL1 (red), in the same orientation as in panel a, with the amino acid side chains of the CX3C motif shown as sticks and colored yellow. **(C)** Structure of RSV G¹⁶¹⁻¹⁹⁷ (cyan), with the amino acid side chains of the CX3C motif shown as sticks and colored yellow. Images in panels B and C are shown at the same magnification.

| Α | | | В | - | | | | |
|---------|---|------------------------------|-------------------------------|---|--|--|--|--|
| RSV G16 | 1-197 NDFHFE | EVFNFVPCSICSNNPTCWAIC | KRIPNKKPGK | 2 | (2) | | | |
| RSVA | | | | | | | | |
| RSVL | | | | | | | | |
| RSV2 | | | | | | | | |
| RSV4 | RSV3 NDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGK RSV4 NDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGK | | | | | | | |
| RSV5 | | | | | | | | |
| RSV6 | | | | | | | | |
| RSV7 | | | | | | | | |
| RSV8 | | | | | | | | |
| | RSVI DDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKK | | | | | | | |
| RSVB | RSVB DDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKK | | | | | | | |
| | | | | | | | | |
| С | | | | | | | | |
| mAb | Linear | Linear Epitope | Conformational | Strain(s) | Reference | | | |
| | Epitope ^a | Sequence | Epitope Sequence ^b | Specificity | STATES AND A STATE OF THE STATES AND A STATES AND A STATE OF THE STATES AND A STATE OF THE STATES AND A STATE | | | |
| 3D3 | 164-172 | HFEVFNFVP | NDF-FEVFNFVP-SI- | RSV A, B | Collarini et al. 2009 | | | |
| | | AC 45 VII. 184 VII. 184 VII. | N-TCI-K-IP | No. 10 - Charles and the control of | Commende was completely with the Area. | | | |
| 2B11 | 162-172 | DFHFEVFNFVP | | RSV A, B | Collarini et al. 2009 | | | |
| 1G8 | 164-172 | HFEVFNFVP | | RSV A, B | Collarini et al. 2009 | | | |
| 10C6 | 165-169 | FEVFN | | RSV A, B | Collarini et al. 2009 | | | |
| 1D4 | 165-171 | FEVFNFV | | RSV A, B | Collarini et al. 2009 | | | |
| 3G12 | 167-176 | VFNFVPCSIC | | RSV A, B | Collarini et al. 2009 | | | |
| 1F12 | 166-172 | EVFNFVP | | RSV A, B | Collarini et al. 2009 | | | |
| 1A5 | 161-170 | -NDFHFEVFNF | | RSV A, B | Collarini et al. 2009 | | | |
| 5D8 | 160-169 | NNDFHFEVFN | | RSV A, B | Collarini et al. 2009 | | | |
| 2D10 | N.D. | N.D. | CSNNPT-WAICKR | RSV A, B | Collarini et al. 2009 | | | |
| 1G1 | N.D. | N.D. | | RSV A, B | Collarini et al. 2009 | | | |
| 6A12 | N.D. | N.D. | | RSV A, B | Collarini et al. 2009 | | | |
| AT34 | 161-170 | -NDFHFEVFNF | | RSV A, B | Cortjens et al. 2017 | | | |
| AT40 | 162-170 | DFHFEVFNF | | RSV A, B | Cortjens et al. 2017 | | | |
| AT64G | 162-170 | DFHFEVFNF | | RSV A, B | Cortjens et al. 2017 | | | |
| AT50 | 175-184 | -ICSNNPTCWA- | | RSV A | Cortjens et al. 2017 | | | |
| AT51 | 174-184 | SICSNNPTCWA- | | RSV A | Cortjens et al. 2017 | | | |
| AT61G | 174-184 | SICSNNPTCWA- | | RSV A | Cortjens et al. 2017 | | | |

^a Linear epitope seguence numbering in RSV strain A2. N.D. refers to no detectable binding to linear RSV

RSV A

RSV A

RSV A, B

Cortjens et al. 2017

Cortjens et al. 2017

Cortjens et al. 2017

AT32

AT33

AT42

71

72

73

74

75

76

77

78

185-193

186-193

N.D.

ICKRIPNKK---

-CKRIPNKK---

^c References for linear epitope sequence mapping.

Fig. S5. Isolated human anti-G mAbs and epitope characterization. (A) Sequence alignment of RSV G CCD from diverse RSV strains, colored by linear epitope clustering in three regions. (B) Structure of RSV G161-197, colored as in panel a, revealing the overlap of linear epitopes in three-dimensional space. (C) Table of 21 isolated human anti-G mAbs, their linear epitope sequences, and their RSV strain specificity.

G peptides.

^b Conformational epitope sequences were determined in this study.

Table S1. Crystallographic data collection and refinement statistics^a

| | 3D3-RSV G ¹⁶²⁻¹⁷² | 3D3-RSV G ¹⁶¹⁻¹⁹⁷ | 2D10-RSV G ¹⁶⁹⁻¹⁹⁸ |
|--|------------------------------|------------------------------|-------------------------------|
| PDB code | 5WNB | 5WNA | 5WN9 |
| Data collection ^b | | | |
| Space group | $P2_{1}2_{1}2_{1}$ | $P2_1$ | $P2_{1}2_{1}2_{1}$ |
| Cell dimensions | | - | |
| a, b, c (Å) | 68.76, 105.43, 121.82 | 64.62, 135.01, 73.78 | 44.84, 56.39, 126.15 |
| α, β, γ (°) | 90, 90, 90 | 90, 107.45, 90 | 90, 90, 90 |
| Resolution (Å) | 48.38 - 2.40 (2.48 - | 48.72 - 2.40 (2.48 - | 50.00 - 1.55 (1.58 - |
| () | 2.40) | 2.40) | 1.55) |
| Total no. reflections | 368,399 | 294,679 | 453,130 |
| No. unique reflections | 40,103 | 46,906 | 47,198 |
| $R_{\text{merge}}^{ c}$ | 0.122 (0.838) | 0.107 (0.763) | 0.058 (0.930) |
| $I / \sigma(I)$ | 13.4 (3.1) | 12.3 (2.2) | 44.0 (1.4) |
| Completeness (%) | 99.9 (99.8) | 99.5 (99.0) | 99.9 (99.4) |
| Redundancy | 9.2 (8.3) | 6.3 (5.6) | 9.6 (6.2) |
| $\operatorname{CC}_{1/2}^{\operatorname{d}}$ | 0.997 (0.808) | 0.996 (0.670) | 0.998 (0.751) |
| Refinement | | | |
| Resolution (Å) | 48.38 - 2.40 | 48.72 - 2.40 | 50.00 - 1.55 |
| No. reflections | 35,325 | 46,869 | 47,114 |
| $R_{ m work}$ / $R_{ m free}^{ m e}$ | 0.224 / 0.267 | 0.192 / 0.246 | 0.169 / 0.185 |
| No. atoms | | | |
| Protein | 6,552 | 7,124 | 3,810 |
| Ligand/ion | 22 | None | None |
| Water | 90 | 135 | 111 |
| <i>B</i> -factors ($Å^2$) | | | |
| Protein: bnmAb | 50 | 41 | 38 |
| Protein: RSV G | 40 | 56 | 48 |
| Ligand/ion | 63 | None | None |
| Water | 35 | 39 | 38 |
| R.m.s. deviations | | | |
| Bond lengths (Å) | 0.005 | 0.006 | 0.008 |
| Bond angles (°) | 0.864 | 0.935 | 0.968 |
| Ramachandran (%) | | | |
| Favored | 96.5 | 97.6 | 99.2 |
| Allowed | 3.5 | 2.4 | 0.8 |
| Outliers | 0 | 0 | 0 |

The following parameters of t